Canada CRISPR Market (2025-2030)
The Canada CRISPR Market was valued at $149.7 Million in 2025 and projected to reach to $239.3 Million by 2030, representing a compound annual growth rate of 9.8%. Canada's CRISPR market is poised for sustained growth through 2030, supported by increasing healthcare investments and a thriving biotechnology ecosystem.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada CRISPR Market Trends and Insights
- Valued at $149.7 million in 2025, Canada's market is expected to expand to $239.3 million by 2030, reflecting a compound annual growth rate of 9.8%.
- This expansion is driven by Canada's robust healthcare infrastructure, increasing investment in biotechnology research, and growing adoption of precision medicine approaches across Canadian medical institutions. Canada's CRISPR sector benefits from strong government support for life sciences innovation and a collaborative ecosystem between academic research centers and commercial entities.
- The Canadian market is characterized by rising demand for gene-therapy applications and therapeutic development, supported by regulatory frameworks that encourage clinical advancement.
- By 2030, Canada is expected to solidify its position as a key player in the North American CRISPR market, with expanding applications in oncology, genetic disorders, and rare disease treatment. The trajectory from 2025 to 2030 demonstrates Canada's commitment to advancing precision medicine and biotechnology innovation.
- Canada's market growth reflects both domestic demand and international partnerships that leverage the country's research capabilities and healthcare expertise..
Key Market Statistics
- CAGR (2025-2030) 9.8% CAGR
- Market Size, 2025 ~USD 149.7 Million
- Forecast, 2030 ~USD 239.3 Million
- Country Canada
Canada CRISPR Market Overview
Market Valuation Growth :
Canada's CRISPR market is valued at $149.7 million in 2025 and is projected to reach $239.3 million by 2030, representing a 59.8% increase over the five-year forecast period.
Strong CAGR Performance :
With a compound annual growth rate of 9.8%, Canada's CRISPR market is expanding steadily, driven by increased adoption of gene-editing technologies in therapeutic applications and research initiatives.
Biotech Investment Hub :
Canada's robust healthcare infrastructure and substantial government funding for biotechnology research position the country as a key innovation center for CRISPR-based therapeutics and diagnostics development.
Clinical Pipeline Expansion :
Canadian research institutions and biotech companies are advancing multiple CRISPR-based clinical trials, contributing to the market's growth and establishing Canada as a leader in gene-editing innovation.
Canada CRISPR Market Dynamics
- The country's strong regulatory framework and academic research capabilities create favorable conditions for CRISPR technology adoption across therapeutic and diagnostic applications.
- Canadian healthcare providers are progressively integrating gene-editing solutions into treatment protocols, particularly for genetic disorders and oncology applications. The market's 9.8% CAGR reflects growing confidence in CRISPR's clinical efficacy and expanding reimbursement pathways.
- Strategic partnerships between Canadian biotech firms and international pharmaceutical companies are accelerating commercialization efforts.
- Government initiatives supporting precision medicine and genomic research further strengthen Canada's position as a competitive CRISPR market, attracting both domestic and foreign investment in gene-editing technologies..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Key Takeaways
- Canada's CRISPR market is valued at $149.7 million in 2025 and is projected to reach $239.3 million by 2030, growing at a 9.8% CAGR.
- Canada's robust healthcare infrastructure and government support for biotechnology research are primary drivers of market expansion.
- Canada's market is increasingly focused on therapeutic applications in oncology, genetic disorders, and rare disease treatment.
- Canada's position within North America is strengthened by collaborative research ecosystems and international partnerships in gene-editing innovation.
CRISPR Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | GRNA SYNTHESIS & CELL LINE DEVELOPMENT (Service) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 11.2% from 2025 to 2030 |
| Largest Segment | PRODUCT (Offering) |
| Market Size Base Year (Billions) | ~USD 3.22 (2025) |
| Revenue Forecast (Billions) | ~USD 5.47 (2030) |
| Segments Covered | Offering, Type, End User, Service, Application, Product |
Canada CRISPR Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Product
- Products
- Service
- Services
By Type
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
By End User
- Academic & Research Institutes
- Other End Users
- Pharmaceutical & Biotechnological Companies
- Pharmaceutical & Biotechnology Companies
By Service
- Grna Synthesis & Cell Line Development
- Other Services
- Screening & Validation
By Application
- Agriculture
- Drug Discovery & Development
- Other Applications
By Product
- Crispr Kits & Enzymes
- Crispr Libraries
- Other Products
CANADA: CRISPR SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 9.8 | 11.8 | 12.9 | 14.3 | 15.7 | 17.4 | 19.2 | 21.2 | 10.4 |
| OTHER END USERS | 10.4 | 12.5 | 13.6 | 14.9 | 16.3 | 17.8 | 19.5 | 21.4 | 9.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 13 | 15.6 | 17.2 | 19.1 | 21.1 | 23.3 | 25.9 | 28.7 | 10.7 |
| TOTAL | 33.3 | 39.9 | 43.8 | 48.3 | 53.1 | 58.5 | 64.5 | 71.2 | 10.2 |
CANADA: CRISPR PRODUCTS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 25.9 | 26.1 | 28.5 | 31.2 | 34.2 | 37.4 | 41 | 45 | 9.6 |
| OTHER END USERS | 33.8 | 34.1 | 37.1 | 40.6 | 44.4 | 48.6 | 53.2 | 58.3 | 9.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 36.5 | 36.8 | 40.3 | 44.4 | 48.8 | 53.6 | 59 | 64.9 | 10 |
| TOTAL | 96.2 | 97 | 105.9 | 116.2 | 127.3 | 139.6 | 153.2 | 168.1 | 9.7 |
Target Audience
- Biotech & Pharmaceutical Companies : Evaluate Canada's CRISPR market potential for product launches, licensing agreements, and R&D investments. Understand local competitive positioning and regulatory requirements for market entry.
- Healthcare Providers & Hospitals : Assess adoption opportunities for CRISPR-based diagnostics and therapeutics. Identify reimbursement pathways and clinical integration strategies specific to Canadian healthcare systems.
- Investment & Venture Capital Firms : Analyze Canada's CRISPR market growth trajectory and funding landscape. Identify promising biotech startups and investment opportunities within the Canadian gene-editing sector.
- Government & Policy Makers : Understand market dynamics to inform healthcare policy, research funding priorities, and regulatory frameworks supporting CRISPR innovation and precision medicine adoption in Canada.
- Academic & Research Institutions : Benchmark Canada's CRISPR research capabilities and commercialization potential. Identify collaboration opportunities and funding mechanisms to advance gene-editing research initiatives.
Reasons to Buy this Report
- Market-Specific Sizing Data : Access precise valuation figures for Canada's CRISPR market with detailed 2025-2030 forecasts, enabling accurate budget allocation and investment planning specific to the Canadian healthcare landscape.
- Competitive Landscape Intelligence : Understand Canada's unique competitive dynamics, including key players, market consolidation trends, and emerging biotech companies driving innovation in the Canadian CRISPR ecosystem.
- Regulatory & Reimbursement Insights : Gain comprehensive knowledge of Canada's regulatory pathways, Health Canada approval processes, and provincial reimbursement strategies essential for market entry and commercialization success.
- Investment Opportunity Assessment : Identify high-growth segments within Canada's CRISPR market, including therapeutic applications, research funding trends, and venture capital activity to guide strategic investment decisions.
- Strategic Partnership Guidance : Discover collaboration opportunities with Canadian research institutions, healthcare systems, and biotech firms to accelerate product development and market penetration in this growing segment.
Frequently asked questions
What is the current size of Canada's CRISPR market in 2025?
Canada's CRISPR market is valued at $149.7 million in 2025, representing a significant segment of North America's gene-editing industry.
What is the projected size of Canada's CRISPR market by 2030?
Canada's CRISPR market is projected to reach $239.3 million by 2030, reflecting a 9.8% compound annual growth rate over the forecast period.
What factors are driving growth in Canada's CRISPR market?
Canada's market growth is driven by robust healthcare infrastructure, government investment in biotechnology, increasing adoption of precision medicine, and strong academic-commercial research collaborations.
Which therapeutic areas are most prominent in Canada's CRISPR market?
Canada's CRISPR applications are increasingly focused on oncology, genetic disorders, and rare disease treatment, supported by clinical development initiatives.
How does Canada's CRISPR market compare to the broader North American market?
Canada represents a key growth segment within North America, with a 9.8% CAGR that reflects strong domestic demand and international partnerships leveraging Canada's research capabilities.
RESEARCH METHODOLOGY
The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.
Secondary Research
Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.
Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.
The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.
Primary Research
Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.
The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:
CRISPR Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.
The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/genome engineering product manufacturers
- CRISPR editing/genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific CRISPR market into countries
- A further breakdown of the Rest of Europe CRISPR market into countries
- A further breakdown of the Rest of Latin America CRISPR market into countries
Get the Full CRISPR Market Report
Full forecast, segment splits, and company analysis for all CRISPR Market.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report